Q-Line Biotech (NSE:QLINE) Piotroski F-Score: N/A (As of Jun. 29, 2026)


NSE:QLINE Q-Line Biotech Ltd NSE:QLINE
12 GF Score
Price ₹546.50
! 2 Warning Signs
View Full Analysis

What is Q-Line Biotech Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Q-Line Biotech has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Q-Line Biotech's Piotroski F-Score or its related term are showing as below:

Q-Line Biotech  (NSE:QLINE) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Q-Line Biotech Piotroski F-Score Related Terms


Q-Line Biotech Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Q-Line Biotech's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q-Line Biotech Piotroski F-Score Chart

Q-Line Biotech Annual Data
Trend Mar23 Mar24 Mar25
Piotroski F-Score
0.00 0.00 0.00

Q-Line Biotech Semi-Annual Data
Mar23 Mar24 Mar25
Piotroski F-Score 0.00 0.00 0.00

NSE:QLINE vs ABT, SYK, MDT: Piotroski F-Score Comparison

For the Medical Devices subindustry, Q-Line Biotech's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Q-Line Biotech Piotroski F-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Q-Line Biotech's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Q-Line Biotech's Piotroski F-Score falls into.


NSE:QLINE
12GF Score
Q-Line Biotech Ltd NSE:QLINE
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar25) TTM:Last Year (Mar24) TTM:
Net Income was ₹281 Mil.
Cash Flow from Operations was ₹-13 Mil.
Revenue was ₹3,138 Mil.
Gross Profit was ₹1,323 Mil.
Average Total Assets from the begining of this year (Mar24)
to the end of this year (Mar25) was (3392.46 + 4554.859) / 2 = ₹3973.6595 Mil.
Total Assets at the begining of this year (Mar24) was ₹3,392 Mil.
Long-Term Debt & Capital Lease Obligation was ₹824 Mil.
Total Current Assets was ₹2,646 Mil.
Total Current Liabilities was ₹1,791 Mil.
Net Income was ₹344 Mil.

Revenue was ₹2,036 Mil.
Gross Profit was ₹832 Mil.
Average Total Assets from the begining of last year (Mar23)
to the end of last year (Mar24) was (2515.796 + 3392.46) / 2 = ₹2954.128 Mil.
Total Assets at the begining of last year (Mar23) was ₹2,516 Mil.
Long-Term Debt & Capital Lease Obligation was ₹351 Mil.
Total Current Assets was ₹1,985 Mil.
Total Current Liabilities was ₹1,403 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Q-Line Biotech's current Net Income (TTM) was 281. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Q-Line Biotech's current Cash Flow from Operations (TTM) was -13. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar24)
=281.309/3392.46
=0.08292183

ROA (Last Year)=Net Income/Total Assets (Mar23)
=344.492/2515.796
=0.13693161

Q-Line Biotech's return on assets of this year was 0.08292183. Q-Line Biotech's return on assets of last year was 0.13693161. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Q-Line Biotech's current Net Income (TTM) was 281. Q-Line Biotech's current Cash Flow from Operations (TTM) was -13. ==> -13 <= 281 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=824.118/3973.6595
=0.20739522

Gearing (Last Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=350.93/2954.128
=0.11879309

Q-Line Biotech's gearing of this year was 0.20739522. Q-Line Biotech's gearing of last year was 0.11879309. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar25)=Total Current Assets/Total Current Liabilities
=2646.383/1791.432
=1.47724446

Current Ratio (Last Year: Mar24)=Total Current Assets/Total Current Liabilities
=1985.315/1402.775
=1.41527686

Q-Line Biotech's current ratio of this year was 1.47724446. Q-Line Biotech's current ratio of last year was 1.41527686. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Q-Line Biotech's number of shares in issue this year was 23.328. Q-Line Biotech's number of shares in issue last year was 23.328. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1323.23/3137.804
=0.42170575

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=832.176/2036.461
=0.40863832

Q-Line Biotech's gross margin of this year was 0.42170575. Q-Line Biotech's gross margin of last year was 0.40863832. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar24)
=3137.804/3392.46
=0.92493471

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar23)
=2036.461/2515.796
=0.80946985

Q-Line Biotech's asset turnover of this year was 0.92493471. Q-Line Biotech's asset turnover of last year was 0.80946985. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+0+0+0+0+1+1+1+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Q-Line Biotech has an F-score of 5 indicating the company's financial situation is typical for a stable company.


Q-Line Biotech Business Description

Address Kanpur Road Adjacent Transport Nagar Metro Station, 298-281, Transport Nagar, Lucknow, UP, IND, 226012
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
12GF Score

Get the complete analysis for NSE:QLINE

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹546.50
Price